NIH to Begin Human Trials for Kratom Compound in Opioid Disorder Treatment

The National Institutes of Health has received FDA clearance for its Investigational New Drug application concerning mitragynine. This approval enables an NIH-led Phase I clinical trial to assess the kratom compound's potential as a treatment for opioid use disorder. This development represents a notable step in exploring new therapeutic avenues for this condition.